Quick Answer
BIOCRYST PHARMACEUTICALS INC reported Long Term Debt of $0.00 for the year ending 2025.
- BIOCRYST PHARMACEUTICALS INC showed a decrease of -100.0% in Long Term Debt from 2024 to 2025.
- This data is from BIOCRYST PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $123.04 million | Q2 2021: $126.80 million | Q3 2021: $132.05 million | Q1 2022: $140.24 million | Q2 2022: $144.52 million | Q3 2022: $223.87 million | Q1 2023: $232.52 million | Q2 2023: $293.18 million | Q3 2023: $298.00 million | Q1 2024: $308.48 million | Q2 2024: $313.82 million | Q3 2024: $314.33 million | Q1 2025: $315.41 million | Q2 2025: $242.79 million | Q3 2025: $194.37 million.
- Historical annual values: Fiscal year 2025: $0.00 | Fiscal year 2024: $314.87 million | Fiscal year 2023: $303.23 million | Fiscal year 2022: $231.62 million | Fiscal year 2021: $136.08 million | Fiscal year 2020: $119.74 million | Fiscal year 2019: $0.00.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: